EUVIMEDEUVIMED entdecken
Open Access

The Combined Use of Levodopa/Benserazide and Pramipexole Proves Beneficial for Managing Parkinson's Disease

Qiang Liu, Haiping Wang, Shengyin Lv, Yanyan Zhao, Yabin Zheng, Guanyu Li, Wei Wang

Actas Españolas de Psiquiatría · 2024

DOI: 10.62641/aep.v52i6.1711 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Actas Españolas de Psiquiatría, 2024. Verfasst von Qiang Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, 210003 Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Parkinson Disease, Pramipexole, Benserazide, Levodopa. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Parkinson's disease (PD), a prevalent neurological condition, is characterized by the progressive degeneration of dopamine-producing neurons, leading to motor dysfunction and non-motor symptoms. Therefore, this study aimed to evaluate the impact of combining levodopa/benserazide with pramipexole on PD patients, focusing on cognitive function, plasma monoamine neurotransmitter levels, and serum growth differentiation factor-15 (GDF-15) and angiopoietin-1 (Ang-1) levels.

Methods

This retrospective study included 120 PD patients admitted to the hospital between January 2021 and January 2023. Based on the treatment approaches, the patients were categorized into the control group (n = 61) and the observation group (n = 59). The control group received oral levodopa/benserazide tablets, while the observation group was treated with levodopa/benserazide tablets combined with pramipexole. The two experimental groups were assessed and compared across several parameters, including PD symptoms [Unified Parkinson's Disease Rating Scale (UPDRS)], cognitive function [Montreal Cognitive Assessment (MoCA)], the levels of plasma monoamine neurotransmitters, and serum GDF-15 and Ang-1 levels.

Results

The response rate to treatment was more significant in the observation group (96.55%) compared to the control group (87.93%, p = 0.162). Post-treatment, both groups demonstrated a decline in their UPDRS and overall scores, with the observation group indicating substantially lower scores than the control group (p < 0.05). Furthermore, both groups showed improvements in MoCA scores, with the observation group exhibiting higher scores than the control group (p < 0.05). Similarly, we observed significantly increased dopamine, 5-hydroxytryptamine, and norepinephrine levels in both groups, with the observation group showing a more pronounced increase (p < 0.05). Additionally, we observed a significant decrease in serum GDF-15 levels and an increase in Ang-1 levels across both groups after treatment. However, the observation group exhibited lower GDF-15 levels and higher Ang-1 levels than the control group (p < 0.05).

Conclusions

The combined use of levodopa/benserazide and pramipexole proves beneficial for managing PD. This therapeutic regimen can improve cognitive abilities and plasma monoamine neurotransmitter levels in PD patients, reduce brain tissue damage and decrease serum levels of GDF-15.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseasePramipexoleBenserazideLevodopaAntiparkinson AgentsDrug CombinationsDrug Therapy, CombinationHumansFemaleMaleRetrospective StudiesAgedMiddle AgedGrowth Differentiation Factor 15Cognition

Substanzen

PramipexoleBenserazideLevodopaAntiparkinson AgentsDrug Combinationsbenserazide, levodopa drug combinationGrowth Differentiation Factor 15

Autor:innen und Institutionen

  • Department of Neurology, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, 210003 Nanjing, Jiangsu, China.
  • Department of Neurology, The Affiliated Hospital of Qingdao University, 266003 Qingdao, Shandong, China.

Zitieren

APA

Liu, Q., Wang, H., Lv, S., Zhao, Y., Zheng, Y., Li, G., & Wang, W. (2024). The Combined Use of Levodopa/Benserazide and Pramipexole Proves Beneficial for Managing Parkinson's Disease. Actas Españolas de Psiquiatría. https://doi.org/10.62641/aep.v52i6.1711

Vancouver

Liu Q, Wang H, Lv S, Zhao Y, Zheng Y, Li G, et al. The Combined Use of Levodopa/Benserazide and Pramipexole Proves Beneficial for Managing Parkinson's Disease. Actas Españolas de Psiquiatría. 2024. doi:10.62641/aep.v52i6.1711

BibTeX
@article{Liu2024,
  author = {Liu, Qiang and Wang, Haiping and Lv, Shengyin and Zhao, Yanyan and Zheng, Yabin and Li, Guanyu and Wang, Wei},
  title = {The Combined Use of Levodopa/Benserazide and Pramipexole Proves Beneficial for Managing Parkinson's Disease},
  journal = {Actas Españolas de Psiquiatría},
  year = {2024},
  doi = {10.62641/aep.v52i6.1711}
}
Kostenlos starten →